FINWIRES · TerminalLIVE
FINWIRES

RBCキャピタル・マーケッツは、Utz Brandsの基盤となる成長は依然として堅調だと述べている。

By

-- RBCキャピタル・マーケッツは木曜日のレポートで、Utz Brands(UTZ)の四半期累計の動向は軟調に見えるものの、流通網の拡大、イノベーション、カリフォルニア州での事業拡大の勢いに支えられ、基調的な成長は堅調に推移していると述べた。 同レポートによると、経営陣は新製品が売上高の伸びを支え、燃料、農産物、輸送費については年間を通して十分なコストヘッジができているため、インフレ懸念は緩和されると楽観視している。 スナック菓子部門の通期ガイダンスは依然としてほぼ横ばいの成長を想定しており、アナリストは第1四半期の変動と消費者環境を考慮すると妥当な判断だと述べている。 概ね予想通りの第1四半期決算とガイダンスの再確認を受け、RBCキャピタル・マーケッツは2026年の業績予想を修正し、オーガニック売上高成長率2.5%、EBITDA成長率6%、EPS減少率4.1%を反映させると発表した。 RBCキャピタル・マーケッツは同社株の投資判断を「アウトパフォーム」に据え置き、目標株価を15ドルとした。ウッツ・ブランズの株価は木曜日の取引で5%下落した。

Price: $7.88, Change: $-0.42, Percent Change: -5.06%

Related Articles

Sectors

Sector Update: Consumer Stocks Edge Lower Late Afternoon

Consumer stocks were edging down late Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) each decreasing 0.1%.In corporate news, Tapestry (TPR) raised its fiscal 2026 outlook after delivering a Q3 beat, but provided a subdued Q4 sales guidance for its Kate Spade brand. Its shares dropped more than 13%.Shake Shack (SHAK) shares slumped 28% after the company's Q1 results missed Wall Street estimates.Planet Fitness (PLNT) shares tumbled 32% after the company tempered its full-year outlook amid fewer-than-expected member additions in Q1.McDonald's (MCD) reported better-than-expected Q1 results as comparable sales rebounded more than market estimates despite what the company described as a "challenging" environment. Its shares rose 0.3%.

$MCD$PLNT$SHAK$TPR
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA$TRDA
Research

Cascades Target Eased To C$13 From $14, Keeps Sector Perform at National Bk Which Notes Q1 In Line With Reduced Outlook, Soft Q2 Outlook Before Recovery, Asset Sales Done By Q3

Price: $10.72, Change: $-0.23, Percent Change: -2.10%

$CAS.TO